DMK Pharmaceuticals Corporation

LSE:0A4X Stock Report

Market Cap: US$10.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DMK Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

DMK Pharmaceuticals has a total shareholder equity of $-5.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.0M and $13.9M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$6.66m
Equity-US$4.96m
Total liabilitiesUS$13.92m
Total assetsUS$8.96m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 0A4X has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0A4X has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0A4X is debt free.

Reducing Debt: 0A4X's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 0A4X has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 0A4X has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies